{"podcast":{"title":"Oncology Today with Dr Neil Love","slug":"oncology-today-with-dr-neil-love-1004241","podcast_index_feed_id":1004241,"rss_url":"https://feeds.captivate.fm/oncologytoday/","website_url":"https://www.researchtopractice.com","image_url":"https://artwork.captivate.fm/464a03b3-1b7f-4b39-a2c6-e3de4b1e77b7/8YAjpM6wBeZeb3Gyb3zbR3bE.jpg","author":"Dr. Neil Love","episode_count":463,"summary":"Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.","last_synced_at":"2026-07-28T06:21:37.419138+00:00","page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241"},"episode":{"title":"HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy","slug":"her2-positive-metastatic-breast-cancer-an-interview-with-prof-dr-sibylle-loibl-on-first-line-and-maintenance-therapy","published_at":"2026-07-17T13:00:00+00:00","page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/her2-positive-metastatic-breast-cancer-an-interview-with-prof-dr-sibylle-loibl-on-first-line-and-maintenance-therapy","show_page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241","url":"https://oncologytoday.captivate.fm/episode/6091-oncologytodayfirstlineher2posmbc26","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/3fcfc54e-efea-4da8-8757-29dc956d19f9.mp3","summary":"Featuring an interview with Prof Dr Sibylle Loibl, including the following topics: Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00) Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35) Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01) Targeting the PI3K signaling pathway in HER2-positive mBC (11:08) Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53) Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44) Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54) Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03) CME information and select publications","meta_description":"Featuring an interview with Prof Dr Sibylle Loibl, including the following topics: Perspectives on overall survival gains achieved over the years for pati…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2788,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/her2-positive-metastatic-breast-cancer-an-interview-with-prof-dr-sibylle-loibl-on-first-line-and-maintenance-therapy/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/her2-positive-metastatic-breast-cancer-an-interview-with-prof-dr-sibylle-loibl-on-first-line-and-maintenance-therapy.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}